CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing safe and effective innate immune activators for cancer therapy. By creating activators that can be selectively activated at tumor sites, the aim is to enhance immune responses against various cancers while minimizing systemic toxicity.
Immune therapies have caused a paradigm shift in the treatment of melanoma and leukemias.
However, the broad Immune therapies have caused a paradigm shift in the treatment of melanoma and leukemias.
However, the broad application of these immune therapies to all cancers has not worked.
One of the major reason for this failure is the presence of innate immune suppressive cell types in many tumour types, such as macrophages, NK-, dendritic, and myeloid cells.
Tumour selective reactivation of these…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
